Cryptome to collaborate with IMB
Tuesday, 07 December, 2004
Cryptome (ASX: CRP) has signed a memorandum of understanding with the Institute of Molecular Bioscience (IMB) to collaborate on the identification of cardiovascular therapeutics.
The company will combine the high throughput screening capabilities of Cryptomics platform technology, which is based on the identification of small protein fragments with previously undiscovered therapeutic activity, with the IMB's compound libraries, to identify compounds with therapeutic potential in the treatment of cardiovascular disease.
"Bringing together IMB's novel compound libraries and our screening capabilities will make a powerful combination in a most important clinical area," said Cryptome's acting CEO Prof Mathew Vadas.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
